Relationship between echocardiographic characteristics and cardiac biomarkers during long-distance trail running

Romain Jouffroy¹,²,³*, Hélène Hergault³,⁴, Juliana Antero², Antoine Vieillard Baron¹,³ and Nicolas Mansencal³,⁴

¹Intensive Care Unit, Ambroise Paré Hospital, Assistance Publique—Hôpitaux de Paris (AP-HP), Université de Versailles-Saint Quentin (UVSQ), Boulogne-Billancourt, France; ²IRMES - Institute for Research in Medicine and Epidemiology of Sport, INSEP, Paris, France; ³INSERM U-1018, CESP, Clinical Epidemiology, Université de Versailles-Saint Quentin (UVSQ), Villejuif, France; ⁴Department of Cardiology, Ambroise Paré Hospital, AP-HP, Centre de Référence des Cardiomyopathies et des Troubles du Rythme Cardiaque Héritaires ou Rares, Université de Versailles-Saint Quentin (UVSQ), Boulogne-Billancourt, France

Background: Even if the beneficial cardiovascular effects of moderate exercise are recognized, effects of prolonged and intense exercise are still debated. This study aims to detect cardiovascular changes associated with long endurance running by assessing the relationship between echocardiographic parameters and cardiac biomarkers during long-distance trail running.

Methods: We performed a prospective observational study that included 20 participants who were all amateur runners (median age of 41 years old, still alive after a 7-year clinical follow-up) from 80-km trail running. All the participants underwent an echocardiographic examination and venous blood sampling before the race, at the intermediate refreshment checkpoints of the race (21st and 53rd km), and within 10 min after arrival.

Results: Mitral E/A velocity ratio and mitral TDI e’ wave were significantly decreased at the 21st km to arrival (p < 0.05). Mitral S wave and global longitudinal strain (GLS) were significantly decreased from the 53rd km to arrival (p < 0.05 for 53rd and 80th km). As compared to baseline, T-troponin and NT-proBNP were significantly increased at the 21st km in all the participants, but T-troponin values were systematically increased above the significative threshold. Diastolic echocardiographic abnormalities were mainly observed among participants with highest NT-proBNP (> 77 ng.l⁻¹) values at the 21st km. As compared to baseline, mitral e’ wave was significantly decreased (~35%) in participants with highest values of NT-proBNP. Similarly, GLS was also decreased among participants with highest troponin values at the 53rd km (p = 0.01 for 53rd km and p = 0.04 for arrival).
**Conclusion:** During the long-distance trail running, the early LV decrease in diastolic echocardiographic parameters is associated with increase in NT pro-BNP blood levels, and the decrease in LV systolic echocardiographic parameters later is associated with increase in T-troponin blood levels.

**KEYWORDS**

echocardiographic, biomarker, running, long distance, relation

**Introduction**

In the last 10 years, long-distance running races (i.e., races of at least 6 h) (1) became more popular all over the world (2). This increase of practice has also been observed among individuals older than 45 years old, currently representing around 50% of the participants in marathons and long-distance running races (3). Beneficial cardiovascular effects of moderate exercise are recognized (4), while cardiovascular effects of prolonged and intense exercise remains debated (5–7). Physical activity such as long-term endurance sport practice induces a cardiac remodeling named “athlete’s heart” (8–10), mainly concerning the left ventricle (LV), but also right ventricle (RV) by inducing right ventricular remodeling (11), even if clinical significance is unclear (12, 13). We have previously found that echocardiographic LV systolic and diastolic abnormalities may occur in amateur ultra-distance trail runners (14), and may also impact the RV, because intense exercise-induced right ventricular remodeling is a potential adaptation of cardiac function and structure.

In myocardial injury and septic shock, troponin levels are closely correlated with myocardial injury (15–17). Troponin elevation may result from several mechanisms: parietal mechanical stress in response to pressure or volume overload (18), tachycardia (19), massive release of catecholamines (20), direct action of PAMPs (pathogen-associated molecular patterns) or lipopolysaccharides in sepsis (21), or viral, bacterial, or immune myocarditis (22). Previous studies have found a significant increase in cardiac biomarkers [N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin] during long-distance exercises (23, 24), with unclear significance (25, 26). Recently, it has been observed that a troponin exercise-induced increase above the 99th percentile could be an early marker of mortality and cardiovascular events (27) notably in participants with hypertension (28). Nevertheless, these results remain to be discussed (7, 26, 29, 30). To date, no study has reported a relationship between echocardiographic characteristics and cardiac biomarkers in long distance runners. We aim to detect cardiovascular changes associated with long endurance running by assessing the relationship between echocardiographic parameters and cardiac biomarkers during long-distance trail running.

**Materials and methods**

**Study population and study protocol**

We performed a prospective observational study on 20 participants who were all amateur runners in the 80-km Ecotrail of Paris Ile de France© (total climb of 1,500 m with 4 refreshment points). All the participants were electronically recruited by announcement on the race’s website. The protocol was approved by the race’s organization committee, all the participants, the French committee on public safety Paris Ile-de-France IV (Reference: 2014/07), and the National Heart Agency (Number EudraCT: 2014-A00205-42).

All participants who fulfilled the following criteria were included before the race event: age > 18 years, male gender, and previous completion of an ultra-endurance race (distance > 50 km) during the last 12 months. Participants with a medical history (hypertension, cardiomyopathy, heart failure, or valvular heart disease) or with abnormalities detected on the first echocardiographic examination were not included in the study.

**Echocardiographic examination by transthoracic echocardiographic examination**

All the participants underwent a baseline echocardiographic examination (< 24 h of the start of the event) to determine morphological and dynamical echocardiographic parameters and to confirm the inclusion of subjects. Echocardiographic examinations were performed, and venous blood sampling was systematically performed for sample collection before the race, at the intermediate refreshment checkpoints of the race (21st and 53rd km), and within 10 min after arrival. During the race, a 5-min stop at each checkpoint was required for echocardiographic recording and blood sampling.

1 www.traildeparis.com
All the echocardiographic examinations were performed and recorded by a single experienced physician (NM) using VIVID I (GE Medical Systems, Horten, Norway) (14).

Blood sampling

Blood samples were drawn (1 ml/sample), collected, and immediately stored on ice by a nurse in order to be analyzed later. Electrolytes (Na, K, Cl, and HCO₃⁻), creatinine, and urea plasma concentrations, high-sensitivity T-troponin, NT-proBNP, creatine kinase (CK), myoglobin, protein, and C reactive protein (CRP) blood levels were measured with the immunochemiluminescence method (Roche Diagnostics®) within 2 weeks after the end of the race in a central laboratory of a hospital in Paris (France). In accordance with the laboratory’s biological standards, the normal value for troponin was < 14 ng.L⁻¹ and the normal value for NT-proBNP was < 300 ng.L⁻¹.

All the echocardiographic examinations were digitally recorded and independently interpreted by a physician blinded to the clinical and biological status and race results. After the race, all the measurements were performed according to recommendations (30) and averaged over 3 cardiac cycles. Several 2-dimensional (2D) views were consistently recorded: parasternal long-axis view, parasternal short-axis view, and apical 2-, 3-, and 4-chamber views. The following 2D measurements were systematically assessed (13): (1) end diastolic measurements of the interventricular septum and posterior wall of the LV, (2) end systolic LV and left atrial diameters, (3) aorta diameter and aortic outflow tract in the parasternal long-axis view, (4) LV ejection fraction using Simpson’s method, and (5) left atrial diameter. The following Doppler parameters were consistently calculated: (1) E and A waves of mitral inflow and mitral E wave deceleration time, (2) aortic ejection flow (peak of aortic ejection flow and velocity-time integral of aortic flow), allowing for measurement of cardiac output, (3) Doppler tissue imaging of the lateral and septal mitral annuli in the apical 4-chamber view, allowing for average measurement of mitral e’, a’, and S waves and of the E/e’ ratio, and (4) Doppler tissue imaging of the lateral tricuspid annulus in the apical 4-chamber view, allowing for measurement of tricuspid e’, a’, and S waves. Regional and global LV functions were also studied using the longitudinal strain assessed by 2D speckle tracking. For the analysis of myocardial deformation, loops were recorded in standard B mode using 70–80-Hz cadence images. The software tracks the positional changes of natural myocardial acoustic markers. We systematically calculated global longitudinal strain (GLS) from the apical 2-, 3-, and 4-chamber views.

Statistical analysis

Continuous variables were expressed by median and interquartile range (1st quartile–3rd quartile). Categorical data were expressed as absolute value and percentage.

First, bivariate analyses were performed to assess the relationship between each covariate value on km 21, 53, and 80 (within 10 min after the end of the race) compared with baseline value (km 0). Comparisons were performed by paired data analysis based on the Wilcoxon rank test to take into account the repeated measure design of the study. Second, a Wilcoxon-test was performed between significant echocardiography systolic and diastolic parameters and troponin and NT-proBNP blood median values. The median value was chosen to assess the relation between echocardiographic measurements and participants above the median value for T-troponin and NT-proBNP at each evaluation point respectively in order to identify a biological threshold for cardiac burn-out.

All the tests were 2-sided with a statistically significant p-value < 0.05. All the analyses were performed using R 3.4.2 (the R Foundation for Statistical Computing, Vienna, Austria).2

Results

Population characteristics

Twenty male participants at the 80-km Ecotrail of Paris Ile de France© 2014 were included. On 14 March 2014, the day of the race, the weather was clear (no rain), and the temperature was 14 degrees Celsius. No participant had a cardiovascular risk factor. The characteristics of the sample population are presented in Table 1.

2 http://www.R-project.org

| Variable                  | Median | IQR | Min-max values |
|---------------------------|-------|-----|----------------|
| Age (years)               | 41    | 40–46 | 26–58 |
| Weight (kg)               | 74    | 65–79 | 60–88 |
| Height (cm)               | 175   | 172–180 | 167–190 |
| Body surface area (m²)    | 1.93  | 1.78–1.98 | 1.67–2.16 |
| Body mass index (kg.m⁻²)  | 23.8  | 22.0–24.8 | 21.2–24.9 |
| Training (hours.week⁻¹)   | 5     | 4–6  | 1–14 |
| Training (km.week⁻¹)      | 50    | 40–60 | 10–75 |
| Duration of the race (hours.min) | 11.1 | 9.1–11.8 | 9.09–12.41 |
| Average speed of the race (km.h⁻¹) | 7.4 | 6.6–8.3 | 6.3–8.8 |

Results are expressed by median and interquartile (IQR) range (1st–3rd quartile), and minimal (min) and maximal (max) values.
TABLE 2  Echocardiographic characteristics of the 20 amateur ultra-distance and trail runners.

| Variable                          | Baseline (n = 20) | Km 21 (n = 20) | Km 53 (n = 20) | Km 80 (n = 20) |
|-----------------------------------|------------------|---------------|---------------|---------------|
| **End-diastolic measurements**    |                  |               |               |               |
| Interventricular septum (mm)      | 9.9 (9.0–10.3)   | 9.6 (8.9–10.3)* | 9.4 (8.8–9.9) | 9.5 (8.8–10.0) |
| Posterior wall (mm)               | 9.3 (8.0–10.1)   | 9.2 (8.7–10.2) | 9.1 (8.9–10.1) | 9.9 (9.1–10.1) |
| Left ventricular diameter (mm)    | 48.8 (43.4–51.0) | 45.4 (42.3–47.5) | 44.2 (41.0–46.1) | 44.4 (41.0–48.4)* |
| Left ventricular ejection fraction (%) | 65 (62–66)    | 66 (65–67)    | 63 (60–65)    | 59 (55–62)*    |
| **Doppler measurements**          |                  |               |               |               |
| Mitral S wave (m.s\(^{-1}\))     | 16.0 (15.0–18.0) | 17.0 (13.8–19.3) | 15.5 (13.0–17.3)* | 14.0 (13.0–15.3)* |
| Mitral E wave (m.s\(^{-1}\))     | 0.80 (0.75–0.93) | 0.77 (0.66–0.84) | 0.70 (0.60–0.73) | 0.60 (0.53–0.68)* |
| Mitral A wave (m.s\(^{-1}\))     | 0.61 (0.50–0.66) | 0.76 (0.70–0.82) | 0.72 (0.61–0.86) | 0.62 (0.73–0.73) |
| Mitral E/A ratio                  | 1.02 (0.99–1.06) | 0.98 (0.89–1.07)* | 0.94 (0.82–1.10)* | 0.88 (0.79–1.40)* |
| Mitral TDI e’ wave (m.s\(^{-1}\)) | 0.12 (0.11–0.14) | 0.10 (0.08–0.13)* | 0.09 (0.07–0.14)* | 0.09 (0.08–0.12)* |
| Mitral E/e’ ratio                | 6.3 (5.5–7.6)    | 6.8 (6.1–7.4)  | 6.3 (5.6–7.5)  | 5.9 (5.4–8.6)   |
| Tricuspid TDI e’ wave (m.s\(^{-1}\)) | 0.16 (0.14–0.17) | 0.12 (0.11–0.16) | 0.13 (0.11–0.16) | 0.13 (0.11–0.14) |
| Tricuspid E/e’ ratio             | 5.0 (4.4–5.9)    | 5.5 (5.0–6.3)  | 4.7 (4.4–5.9)  | 5.0 (4.6–5.3)   |
| **Two-dimensional strain measurements** |                  |               |               |               |
| Global peak systolic strain (%)   | -21.5 (–22.3 to –20.0) | -21.2 (–22.7 to –21.6) | -19.9 (–23.4 to –18.9)* | -19.8 (–20.3 to –18.7)* |
| A3C peak systolic strain (%)      | -21.6 (–23.8 to –20.8) | -22.2 (–25.0 to –21.1) | -20.6 (–24.3 to –19.3)* | -20.6 (–21.6 to –18.9)* |
| A4C peak systolic strain (%)      | -21.0 (–22.8 to –19.3) | -21.9 (–23.4 to –20.7) | -20.1 (–21.1 to –17.9)* | -19.0 (–20.2 to –18.3)* |
| A2C peak systolic strain (%)      | -21.9 (–23.2 to –20.8) | -20.8 (–23.9 to –21.5) | -20.5 (–28.4 to –19.6) | -20.3 (–21.5 to –17.9)* |

A2C, apical 2-chamber view; A3C, apical 3-chamber view; and A4C, apical 4-chamber view. *For p-value < 0.05 with baseline.

Results are expressed by median and IQR range (1st–3rd quartile).

All the participants reached the finish line. They were middle aged (median age of 41 years old), quite slim (median BMI of 23.8 kg.m\(^{-2}\)), and well-trained with regular practice of running (median of 5 h and 50 km running per week; Table 1). On 1 January 2022, all the participants were still alive with regular long-distance practice: annual mean of 5 ± 3 long-distance running races.

Echocardiographic parameters

The evolution of blood parameters from baseline to arrival are presented in Table 2. We observed significant modifications in diastolic function at the 21st km and of systolic function at the 53rd km. Mitral E/A velocity ratio and mitral TDI e’ wave were significantly decreased from 21 to 80 km (p < 0.05). Mitral S wave and GLS absolute values were significantly decreased from the 53rd km to arrival (p < 0.05 for the 53rd and 80th km), contrary to LVEF (p < 0.05 only on the 80th km). All the systolic function parameters were significantly decreased at arrival.

Biological parameters

The evolution of blood parameters from baseline to arrival are presented in Table 3. In comparison with the baseline value, troponin and NT-proBNP were significantly increased at the 21st km in all the participants. While the T-troponin values remained relatively stable, we observed a significant progressive and constant increase in NT-proBNP values during the race. T-troponin values increased above the significative threshold (N < 14 ng.l\(^{-1}\)) in all the participants at the 21st km contrary to the NT pro-BNP values, which remained below the threshold (N < 300 ng.l\(^{-1}\)) in all the participants all along the race.

Muscle biomarkers values (myoglobin, creatinine, and CK) were also above the lower normal value at the 21st km and progressively increased until the end of the race. A systemic inflammation appeared at the 53rd km suggested by the significant and progressive increase in CRP, but no significant association with echocardiographic abnormalities was observed. Urea and creatinine were also progressively increased from the 21st km to the end of the race.

Relationship between echocardiographic parameters and cardiac biomarkers

Diastolic echocardiographic abnormalities (E/A and mitral TDI e’ wave) were mainly observed among participants with NT-proBNP above the median value at the 21st km. As compared to baseline, mitral e’ wave was significantly decreased (–35%) in participants with NT-proBNP above the median value, whereas in participants with NT-proBNP values below the median value, no decrease in mitral e’ wave was observed (Table 4 and...
TABLE 3 | Evolution of biomarkers in the 20 amateur ultra-distance and trail runners.

| Variable                  | Baseline   | Km 21 (n = 20) | Km 53 (n = 20) | Km 80 (n = 20) |
|---------------------------|------------|----------------|----------------|----------------|
| Sodium (mmol·l⁻¹)         | 143 (141–145) | 143 (141–144) | 146 (142–150) | 139 (137–145) |
| Potassium (mmol·l⁻¹)      | 4.6 (4.4–5.1)  | 5.8 (5.1–7.1)  | 4.8 (4.5–4.9)  | 4.6 (4.3–5.0)  |
| Urea (mmol·l⁻¹)           | 5.4 (4.5–6.4)  | 5.8 (5.1–7.1)* | 8.2 (7.2–9.2)* | 9.4 (7.8–10.6)*|
| Creatinine (mmol·l⁻¹)     | 88 (81–97)   | 106 (94–131)*  | 131 (110–153)* | 116 (98–132)*  |
| Proteins (g·l⁻¹)          | 76 (70–82)   | 77 (76–80)     | 76 (73–79)     | 73 (70–74)     |
| C reactive protein (ng·l⁻¹)| 0 (0–0)     | 0 (0–0)        | 1.5 (0–2.1)*   | 6.2 (3.9–8.3)* |
| High-sensitivity T-troponin (ng·l⁻¹)| 8.3 (2.1–12.2) | 15.9 (10.8–20.1)* | 23.2 (17.4–38.5)* | 19.0 (13.9–33.7)* |
| Brain natriuretic peptide (pg·ml⁻¹)| 0 (0–0) | 0 (0–3.1) | 2.7 (0.6–5.0)* | 5.8 (2.7–9.7)* |
| N-terminal pro-brain natriuretic peptide (ng·l⁻¹)| 19 (16–20) | 62 (47–75)* | 91 (80–105)* | 112 (90–136)* |
| Myoglobin (microg·l⁻¹)    | 25 (16–31)  | 170 (138–228)* | 1,115 (580–1,942)* | 1,428 (989–2,717)* |
| Creatine kinase (ng·ml⁻¹)| 14 (9–16)   | 12 (11–17)     | 25 (22–30)*    | 64 (25–72)*    |

*For p-value < 0.05 with baseline. Results are expressed by median with interquartile range (1st–3rd quartile).

TABLE 4 | Relationship between echocardiographic parameters and cardiac biomarkers.

| Variable                      | NT-proBNP < median value N = 10 | NT-proBNP > median value N = 10 | P     |
|-------------------------------|----------------------------------|----------------------------------|-------|
| **Mitral E/A, m.s⁻¹**         |                                  |                                  |       |
| Baseline                      | 1.32 (1.23–1.56)                 | 1.49 (1.32–1.63)                 | 0.063 |
| Km 21                         | 0.99 (0.88–1.06)                 | 1.01 (0.93–1.13)                 | 0.006 |
| Km 53                         | 0.84 (0.78–0.90)                 | 1.10 (0.94–1.12)                 | 0.004 |
| Km 80                         | 0.84 (0.71–0.89)                 | 1.03 (0.84–1.07)                 | 0.006 |
| **Mitral TDI e’ wave (m.s⁻¹)**|                                  |                                  |       |
| Baseline                      | 0.16 (0.14–0.17)                 | 0.17 (0.15–0.18)                 | 0.062 |
| Km 21                         | 0.15 (0.12–0.18)                 | 0.11 (0.10–0.12)                 | 0.005 |
| Km 53                         | 0.15 (0.13–0.18)                 | 0.11 (0.10–0.12)                 | 0.004 |
| Km 80                         | 0.15 (0.14–0.18)                 | 0.12 (0.11–0.13)                 | 0.005 |
| **Variable**                  |                                  |                                  |       |
| **Global long. strain (%)**   |                                  |                                  |       |
| Baseline                      | -21.6 (-22.7 to -20.2)           | -20.6 (-21.1 to -20.2)           | 0.464 |
| Km 21                         | -22.0 (-22.9 to -21.6)           | -23.0 (-23.8 to -20.6)           | 0.887 |
| Km 53                         | -21.1 (-23.9 to -19.7)           | -19.5 (-19.9 to -18.0)           | 0.012 |
| Km 80                         | -20.1 (-21.0 to -19.9)           | -18.3 (-19.2 to -17.9)           | 0.041 |
| **LVEF (%)**                  |                                  |                                  |       |
| Baseline                      | 66 (61–69)                       | 64 (62–68)                       | 0.763 |
| Km 21                         | 65 (64–66)                       | 66 (64–68)                       | 0.057 |
| Km 53                         | 62 (61–65)                       | 64 (60–65)                       | 0.322 |
| Km 80                         | 62 (61–63)                       | 57 (53–59)                       | 0.001 |

Values are expressed as median value with interquartile range (1st quartile–3rd quartile). Median value of NT-proBNP: 77 ng·l⁻¹ and median value of T-troponin: 20 ng·l⁻¹. Global long. Strain, global longitudinal strain, and LVEF, left ventricular ejection fraction (%).

**Figure 1.** Similarly, GLS was also depressed among participants with T-troponin values above the median value, at the 53rd km (p = 0.01 at the 53rd km and p = 0.04 at arrival) whereas in participants with T-troponin values below the median value, no decrease in GLS was observed (Table 4 and Figures 1, 2). In addition, no significant association was observed between GLS, LVEF, or mitral S wave and NT-proBNP, as well as between mitral TDI e’ wave or mitral E/A and T-troponin.
Discussion

Our study is one of the first to investigate exhaustively echocardiographic and biomarker characteristics during long-distance trail running. The main results are: (1) significant differences in the systolic and diastolic functions were observed during the race, (2) mitral S wave and GLS were significantly decreased from the 53rd km to arrival, and all the systolic function parameters were significantly decreased at arrival, (3) mitral E/A velocity ratio and mitral TDI e’ wave were significantly decreased from the 21st to the 80th km, (4) a significant increase in BNP and troponin was observed during the race, and (5) a relationship was observed between BNP and echocardiographic diastolic parameters and between T-troponin and GLS during the race.

The benefits of a regular and moderate physical activity on health and life expectancy in both sexes and in the general population are recognized and are an integral part of recommendations to improve quality of life (31). A dose-response relationship between the amount of physical activity and associated reduction in all-cause mortality in the general population has been described (32). Thus, on-going physical activity may be a factor in reducing the risk of cardiovascular diseases (31). Over the last decades, long-distance running has been widely practiced by amateur runners, with an increase of approximately 5,200% in the number of ultra-endurance races between 1978 and 2008 run by amateur athletes (2). However, little is known about the immediate and long-term impact of prolonged exercise on the heart.

Left ventricular systolic function is preserved in participants presenting with athlete’s heart. However, despite normal GLS, reduced left ventricular ejection fraction may be observed at rest. Using exercise echocardiography, an improvement of left ventricular ejection fraction is observed, confirming an adaptive mechanism in line with Klenk et al. study results contrary to the abnormalities observed in an acute exercise among untrained participants (33). In a previous study (14), we observed the occurrence of LV systolic and diastolic dysfunctions during long-distance trail running. This process was acute and different from the well-known adaptive athlete’s heart. Interestingly, in this study, we performed serial echocardiographic examinations and biomarker analyses, and we observed an association between echocardiographic and biomarker parameters. In the participants, echocardiographic systolic LV dysfunction was associated with increase in troponin level, whereas echocardiographic diastolic LV dysfunction was associated with increase in NT-proBNP blood levels. However, all the participants did not develop systolic and diastolic dysfunctions; indeed, nearly half of them presented with a pattern of systolic and diastolic echocardiography and biological “burnout” (Table 4), suggesting that mismanagement of prolonged exercise could affect both diastolic and systolic...
functions by transient myocardial injury. During the serial analyses, we observed that biomarker modifications occur earlier during the race than echocardiographic parameters. Despite these acute abnormalities, all the participants performed annually an average of five long-distance running race each year, and no long-term impact was observed 10 years after the race, suggesting that the modifications are reversible (34). Moreover, the progressive increase in urea and creatinine at the 21st km suggests a potential acute kidney injury that occurred during the race even if we were not able to exclude a muscle contribution and/or hydration level influence.

The main limitation of the study is the small number of included participants. A single physician performed the echocardiographic examinations and biomarker analyses during the long-distance trail running with several 5-min “pit stops,” and it was technically impossible to add other participants in the study. It was also impossible to perform a multivariate analysis, because the small number of participants did not allow for meeting the validity conditions of a multivariate analysis and consequently, running speed, a possible confounding factor, could not be taken into account to assess the potential influence of exercise intensity on the observed cardiac abnormalities. Beyond this limitation, this study is the first to assess the echocardiographic and biological cardiac parameter kinetics during a long-distance running race with time-limited stops.

**Conclusion**

In this study, we report an early decrease in diastolic echocardiographic parameters associated with increase in NT pro-BNP blood levels, and a decrease in systolic echocardiographic parameters later associated with increase in troponin blood levels. Blood parameter abnormalities occurred earlier than those of the echocardiographic parameters. Long-distance running race is associated with cardiovascular changes: a transient cardiac, systolic and diastolic, injury, but does not seem to be associated with a long-term health impact.
Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by the French Committee on public safety Paris Île-de-France IV (Reference: 2014/07) and the National Heart Agency (Number EudraCT: 2014-A00205-42). The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

RJ and NM: conceptualization, data curation, writing – original draft preparation, supervision, and validation. RJ and HH: methodology. RJ: software. NM: visualization and investigation. RJ, HH, JA, AV, and NM: writing – review and editing. All authors contributed to the article and approved the submitted version.

Acknowledgments

We thank the Ecotrail de Paris Île de France® race organizers and all the runners involved in the study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. da Fonseca-Engelhardt K, Knechtle B, Rust CA, Knechtle P, Lepers R, Rosenmuller T. Participation and performance trends in ultra-endurance running races under extreme conditions - ‘Spartathlon’ versus ‘Badwater’. Extrem Physiol Med. (2013) 2:15. doi: 10.1186/2046-7648-2-15
2. Schier V. Participation trends of ultra endurance events. Sports Med Arthros Rev. (2019) 27:3–7.
3. Myrstad M, Lochen ML, Graff-Iversen S, Gulvik AK, Thelle DS, Stigum H, et al. Increased risk of atrial fibrillation among elderly Norwegian men with a history of long-term endurance sport practice. Scand J Med Sci Sports. (2014) 24:e338–44. doi: 10.1111/sms.12150
4. Sandvik L, Eriksson J, Thaulow E, Eriksen GS, Mundal R, Rodahl K. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. N Engl J Med. (1993) 328:533–7.
5. Marijon E, Tafflet M, Antero-Jacquemin J, El Helou N, Berthelot G, Celermayer DS, et al. Mortality of French participants in the Tour de France (1947-2012). Eur Heart J. (2013) 34:3145–50. doi: 10.1093/eurheartj/eht347
6. Neilan TG, Yoerger DM, Douglas PS, Marshall JE, Halpern EF, Lawlor D, et al. Increased risk of atrial fibrillation among elderly Norwegian men with a history of long-term endurance sport practice. Scand J Med Sci Sports. (2014) 24:e338–44. doi: 10.1111/sms.12150
7. Dalos D, Dachs T, Gatterer C, Schneider M, Binder T, Bonderman D, et al. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation. (2002) 105:944–9. doi: 10.1161/01.hrc.0000028818.33488.7b
8. Prior DL, La Gerche A. The athlete’s heart. Heart. (2012) 98:947–55. doi: 10.1161/CIRCULATIONAHA.111.009418
9. Pelliccia A, Maron BJ, De Luca R, Di Paolo FM, Spataro A, Calasso F. Remodeling of left ventricular hypertrophy in elite athletes after long-term deconditioning. Circulation. (2002) 105:944–5. doi: 10.1161/01.cir.0000028818.33488.7b
10. Turagam MK, Velagapudi P, Kocheril AG. Atrial fibrillation in athletes. Am J Cardiol. (2012) 109:296–302.
11. Mascia G, Arbelo E, Porta I, Brugada R, Brugada J. The arrhythmogenic right ventricular cardiomyopathy in comparison to the athletic heart. J Cardiovasc Electrophysiol. (2020) 31:1836–43. doi: 10.1111/jce.14526
12. Pelliccia A, Kinoshiita N, Pisichico C, Quattrini F, Di Paolo FM, Ciardo R, et al. Long-term clinical consequences of intense, uninterrupted endurance training in Olympic athletes. J Am Coll Cardiol. (2010) 55:1619–25. doi: 10.1016/j.jacc.2009.10.068
13. O’Keefe JH, Patil HR, Lavie CJ, Magalski A, Vogel RA, McCullough PA. Potential adverse cardiovascular effects from excessive endurance exercise. Mayo Clin Proc. (2012) 87:587–95.
14. Jouffroy R, Caille V, Perrot S, Villiard-Baron A, Dubourg O, Mansencal N. Changes of cardiac function during ultradistance trail running. Am J Cardiol. (2015) 116:1284–9.
15. Mather AN, Fairbairn TA, Artis NJ, Greenwood JP, Plein S. Relationship of cardiac biomarkers and reversible and irreversible myocardial injury following acute myocardial infarction as determined by cardiovascular magnetic resonance. Int J Cardiol. (2013) 166:458–64. doi: 10.1016/j.ijcard.2011.1.004
16. Steen H, Futterer S, Merten C, Jungner C, Katus HA, Giannitsis E. Relative role of NT-pro BNP and cardiac troponin T at 96 hours for estimation of infarct size and left ventricular function after acute myocardial infarction. J Cardiovasc Magn Reson. (2007) 9:749–58. doi: 10.1080/10976640701544589
17. Younger JR, Plein S, Barth J, Ridgway JP, Ball SG, Greenwood JP. Troponin-1 concentration 72 h after myocardial infarction correlates with infarct size and presence of microvascular obstruction. Heart. (2007) 93:1547–51. doi: 10.1136/hrt.2006.109249
18. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulze R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation. (2002) 106:1543–9. doi: 10.1161/01. cor.0000028818.33488.7b
19. Hessel MH, Atsma DE, van der Valk EJ, Bax WH, Schalij MJ, van der Laarse A. Release of cardiac troponin I from viable cardiomyocytes is mediated by integrin stimulation. *Pflugers Arch.* (2008) 455:979–86.

20. Barber M, Morton JJ, Macfarlane PW, Barlow N, Roditi G, Stott DJ. Elevated troponin levels are associated with sympathoadrenal activation in acute ischaemic stroke. *Cerebrovasc Dis.* (2007) 23:260–6. doi: 10.1159/000098325

21. Walley KR. Sepsis-induced myocardial dysfunction. *Curr Opin Crit Care.* (2018) 24:292–9.

22. Elamm C, Fairweather D, Cooper LT. Republished: pathogenesis and diagnosis of myocarditis. *Postgrad Med J.* (2012) 88:539–44. doi: 10.1136/postgradmedj-2012-301686rep

23. Frias MA, Virzi J, Golar O, Gencer B, Mach F, Vuilleumier N. Impact of long distance rowing on biological health: a pilot study. *Clin Biochem.* (2018) 52:142–7. doi: 10.1016/j.clinbiochem.2017.11.018

24. Moreville T, Rosenkilde M, Mattsson N, Dela F, Helge JW, Rasmussen HK. 2706 km cycling in 2 weeks: effects on cardiac function in 6 elderly male athletes. *Phys Sportsmed.* (2018) 46:263–8. doi: 10.1080/00913847.2018.1477403

25. Patil HR, O’Keefe JH, Lavie CJ, Magalski A, Vogel RA, McCullough PA. Cardiovascular damage resulting from chronic excessive endurance exercise. *Mo Med.* (2012) 109:312–21.

26. Predel HG. Marathon run: cardiovascular adaptation and cardiovascular risk. *Eur Heart J.* (2014) 35:3091–8.

27. Aengevaeren VL, Hopman MTE, Thompson PD, Bakker EA, George KP, Thijssen DHJ, et al. Exercise-Induced cardiac troponin i increase and incident mortality and cardiovascular events. *Circulation.* (2019) 140:804–14. doi: 10.1161/CIRCULATIONAHA.119.041627

28. Park MH, Shin KA, Kim CH, Lee YH, Park Y, Ahn J, et al. Effects of long-distance running on cardiac markers and biomarkers in exercise-induced hypertension runners: an observational study. *Ann Rehabil Med.* (2018) 42:575–83. doi: 10.5535/arm.2018.42.4.575

29. Le Goff C, Gergele I, Seidel L, Cavalier E, Kaux JF. Mountain Ultra-Marathon (UTMB) impact on usual and emerging cardiac biomarkers. *Front Cardiovasc Med.* (2022) 9:856223. doi: 10.3389/fcvm.2022.856223

30. Le Goff C, Vailllon M, Kaux JF, Andonian P, Moulin K, Seidel L, et al. Kinetics of cardiac remodeling and fibrosis biomarkers during an extreme mountain ultramarathon. *Front Cardiovasc Med.* (2022) 9:790551. doi: 10.3389/fcvm.2022.790551

31. Nocon M, Hiemann T, Müller-Riemenschneider F, Thalau F, Roll S, Wöllich SN. Association of physical activity with all-cause and cardiovascular mortality: a systematic review and meta-analysis. *Eur J Cardiovasc Prev Rehabil.* (2008) 15:239–46.

32. Wen CP, Wai JP, Tsi MK, Yang YC, Cheng TY, Lee MC, et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. *Lancet.* (2011) 378:1244–53. doi: 10.1016/S0140-6736(11)60749-6

33. Klenk C, Brunner H, Nickel T, Sagmeister F, Yilmaz A, Infanger D, et al. Cardiac structure and function in response to a multi-stage marathon over 4486 km. *Eur J Prev Cardiol.* (2021) 28:1102–9. doi: 10.1177/2047487319885035

34. Rubio-Arias JA, Andreu I, Martinez-Aranda LM, Martinez-Rodriguez A, Manonelles P, Ramos-Campo DJ. Effects of medium- and long-distance running on cardiac damage markers in amateur runners: a systematic review, meta-analysis, and meta-regression. *J Sport Health Sci.* (2021) 10:192–200. doi: 10.1016/j.jshs.2019.10.003